Synthetic biology leader Twist Bioscience disclosed robust Q3 fiscal 2025 results with revenues climbing 18% year-over-year to $96.1 million, driven notably by 27% growth in next-generation sequencing products. The company fine-tuned its full-year revenue guidance to a narrower $374–376 million range citing sustained academic customer engagement and expanding diagnostics demand. With positive net income reversal and decreases in R&D expenses, Twist highlights its positioning to capitalize on growing opportunities within AI-driven drug discovery and synthetic biology arenas.